These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 32782530)

  • 1. Regorafenib treatment outcome for Taiwanese patients with metastatic gastrointestinal stromal tumors after failure of imatinib and sunitinib: A prospective, non-randomized, single-center study.
    Hu CH; Yeh CN; Chen JS; Tsai CY; Wang SY; Cheng CT; Yeh TS
    Oncol Lett; 2020 Sep; 20(3):2131-2142. PubMed ID: 32782530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II Trial of Continuous Regorafenib Dosing in Patients with Gastrointestinal Stromal Tumors After Failure of Imatinib and Sunitinib.
    Kim JJ; Ryu MH; Yoo C; Beck MY; Ma JE; Kang YK
    Oncologist; 2019 Nov; 24(11):e1212-e1218. PubMed ID: 31036770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy.
    Ben-Ami E; Barysauskas CM; von Mehren M; Heinrich MC; Corless CL; Butrynski JE; Morgan JA; Wagner AJ; Choy E; Yap JT; Van den Abbeele AD; Solomon SM; Fletcher JA; Demetri GD; George S
    Ann Oncol; 2016 Sep; 27(9):1794-9. PubMed ID: 27371698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regorafenib: a novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumors.
    Crona DJ; Keisler MD; Walko CM
    Ann Pharmacother; 2013 Dec; 47(12):1685-96. PubMed ID: 24259629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II trial of regorafenib in patients with metastatic and/or a unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17.
    Yeh CN; Chen MH; Chen YY; Yang CY; Yen CC; Tzen CY; Chen LT; Chen JS
    Oncotarget; 2017 Jul; 8(27):44121-44130. PubMed ID: 28487491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of the pretreatment neutrophil-to-lymphocyte ratio in patients with advanced gastrointestinal stromal tumors treated with sunitinib after imatinib failure.
    Sobczuk P; Teterycz P; Lugowska I; Klimczak A; Bylina E; Czarnecka AM; Kosela-Paterczyk H; Osuch C; Streb J; Rutkowski P
    Oncol Lett; 2019 Sep; 18(3):3373-3380. PubMed ID: 31452817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytoreductive Surgery may be beneficial for highly selected patients with Metastatic Gastrointestinal Stromal Tumors receiving Regorafenib facing Local Progression: A Case Controlled Study.
    Yeh CN; Hu CH; Wang SY; Wu CE; Chen JS; Tsai CY; Hsu JT; Yeh TS
    J Cancer; 2021; 12(11):3335-3343. PubMed ID: 33976743
    [No Abstract]   [Full Text] [Related]  

  • 8. A Nomogram Predicting Progression Free Survival in Patients with Gastrointestinal Stromal Tumor Receiving Sunitinib: Incorporating Pre-Treatment and Post-Treatment Parameters.
    Chang YR; Huang WK; Wang SY; Wu CE; Chen JS; Yeh CN
    Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34070456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The BRAF Status May Predict Response to Sorafenib in Gastrointestinal Stromal Tumors Resistant to Imatinib, Sunitinib, and Regorafenib: Case Series and Review of the Literature.
    Franck C; Rosania R; Franke S; Haybaeck J; Canbay A; Venerito M
    Digestion; 2019; 99(2):179-184. PubMed ID: 30179868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival in advanced GIST has improved over time and correlates with increased access to post-imatinib tyrosine kinase inhibitors: results from Life Raft Group Registry.
    Call JW; Wang Y; Montoya D; Scherzer NJ; Heinrich MC
    Clin Sarcoma Res; 2019; 9():4. PubMed ID: 30984366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of Regorafenib in Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib].
    Saito Y; Takahashi T; Tanaka K; Miyazaki Y; Makino T; Kurokawa Y; Yamasaki M; Nakajima K; Takiguchi S; Mori M; Doki Y
    Gan To Kagaku Ryoho; 2018 Jan; 45(1):121-123. PubMed ID: 29362328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Dasatinib With Progression-Free Survival Among Patients With Advanced Gastrointestinal Stromal Tumors Resistant to Imatinib.
    Schuetze SM; Bolejack V; Thomas DG; von Mehren M; Patel S; Samuels B; Choy E; D'Amato G; Staddon AP; Ganjoo KN; Chow WA; Rushing DA; Forscher CA; Priebat DA; Loeb DM; Chugh R; Okuno S; Reinke DK; Baker LH
    JAMA Oncol; 2018 Jun; 4(6):814-820. PubMed ID: 29710216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surgery for metastatic gastrointestinal stromal tumor: to whom and how to?
    Kikuchi H; Hiramatsu Y; Kamiya K; Morita Y; Sakaguchi T; Konno H; Takeuchi H
    Transl Gastroenterol Hepatol; 2018; 3():14. PubMed ID: 29682621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in patients treated with selective internal radiation therapy.
    D'Emic N; Engelman A; Molitoris J; Hanlon A; Sharma NK; Moeslein FM; Chuong MD
    J Gastrointest Oncol; 2016 Apr; 7(2):269-77. PubMed ID: 27034796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regorafenib: A Review of Its Use in Patients with Advanced Gastrointestinal Stromal Tumours.
    Shirley M; Keating GM
    Drugs; 2015 Jun; 75(9):1009-17. PubMed ID: 25998375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of TAS-116, an oral inhibitor of heat shock protein 90, in patients with metastatic or unresectable gastrointestinal stromal tumour refractory to imatinib, sunitinib and regorafenib: a phase II, single-arm trial.
    Doi T; Kurokawa Y; Sawaki A; Komatsu Y; Ozaka M; Takahashi T; Naito Y; Ohkubo S; Nishida T
    Eur J Cancer; 2019 Nov; 121():29-39. PubMed ID: 31536852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytoreductive Surgery for Metastatic Gastrointestinal Stromal Tumors Treated With Tyrosine Kinase Inhibitors: A 2-institutional Analysis.
    Fairweather M; Balachandran VP; Li GZ; Bertagnolli MM; Antonescu C; Tap W; Singer S; DeMatteo RP; Raut CP
    Ann Surg; 2018 Aug; 268(2):296-302. PubMed ID: 28448384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A systematic review and network meta-analysis of post-imatinib therapy in advanced gastrointestinal stromal tumour.
    Shah K; Chan KKW; Ko YJ
    Curr Oncol; 2017 Dec; 24(6):e531-e539. PubMed ID: 29270063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial.
    Reichardt P; Demetri GD; Gelderblom H; Rutkowski P; Im SA; Gupta S; Kang YK; Schöffski P; Schuette J; Soulières D; Blay JY; Goldstein D; Fly K; Huang X; Corsaro M; Lechuga MJ; Martini JF; Heinrich MC
    BMC Cancer; 2016 Jan; 16():22. PubMed ID: 26772734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blood neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios are independent prognostic factors for surgically resected gastrointestinal stromal tumors.
    Goh BK; Chok AY; Allen JC; Quek R; Teo MC; Chow PK; Chung AY; Ong HS; Wong WK
    Surgery; 2016 Apr; 159(4):1146-56. PubMed ID: 26688506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.